Access the Next-Generation of Cancer Diagnostics
One of the major challenges in diagnosing hematological and solid tumor cancers is the high degree of tumor heterogeneity. Mutations that have critical clinical implications may only be present in very low levels, making detection of these mutations difficult. Detection of such mutations is especially important in hematological and solid tumor malignancies, where tumors show a great deal of heterogeneity and accurate prognosis is essential to identifying patient with more aggressive disease.
Next-generation sequencing (NGS) helps respond to these challenges by providing a comprehensive view of the tumor’s genomic profile. Importantly, NGS can detect multiple mutations present at very low levels within the tumor.
Next-Generation sequencing (NGS) performs massively parallel sequencing of genomes, allowing for the analysis of a significant number of genomic targets with a single test. Critically, NGS allows for the detection of aberrations that may only be present at very low levels, but which may have important clinical relevance for the patient’s diagnosis and prognosis.
Focus::NGS™ – Access the Next-Generation of Cancer Diagnostics
Cancer Genetics Principal Clinical Scientist, Dr. Charles Ma, explains some of the major challenges encountered when searching for mutations within tumors.